Download PDF
Thromb Haemost 2006; 96(06): 731-737
DOI: 10.1160/TH06-08-0422
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Tiplaxtinin impairs nutritionally induced obesity in mice

H. Roger Lijnen
1   Center for Molecular and Vascular Biology, KU Leuven, Belgium
,
Marie-Christine Alessi
2   Haematology Laboratory, INSERM U626, Marseille, France; Faculty of Medicine, Marseille, France
,
Liesbeth Frederix
1   Center for Molecular and Vascular Biology, KU Leuven, Belgium
,
Désiré Collen
,
Irène Juhan-Vague
2   Haematology Laboratory, INSERM U626, Marseille, France; Faculty of Medicine, Marseille, France
› Author AffiliationsFinancial support: This study was supported by the “Bijzonder Onderzoeksfonds KU Leuven” (OT/03/48) and by the IWT (SBO Project 040084). Wyeth provided financial support for the studies of H.R.L.
Further Information

Publication History

Received 03 August 2006

Accepted after revision 17 October 2006

Publication Date:
29 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

To investigate the effect of tiplaxtinin, designed as a synthetic inhibitor of plasminogen activator inhibitor-1 (PAI-1), on obesity, male C57Bl/6 mice (13–14 weeks old) were kept on a high-fat diet (20.1 kJ/g) for four weeks without or with addition of tiplaxtinin (PAI-039) at a dose of 2 mg/g food. At the time of sacrifice, body weights were significantly lower in the inhibitor-treated mice (p < 0.0005). The weights of the isolated subcutaneous and gonadal fat deposits were also significantly lower (both p < 0.0005), associated with adipocyte hypotrophy. Inhibitor-treated adipose tissues displayed similar blood vessel size, but a higher blood vessel density. Fasting glucose and insulin levels, as well as glucose-tolerance tests were not significantly affected by the inhibitor treatment, whereas plasma triglyceride levels were significantly reduced (p = 0.02) and LDL-cholesterol levels significantly enhanced (p = 0.0002). Insulin-tolerance tests revealed significantly lower glucose levels at the end of the test in the inhibitor treated mice (p = 0.03). Thus, in this model of diet-in-duced obesity in mice administration of tiplaxtinin resulted in impaired adipose tissue development.

Keywords

PAI-1 - obesity - adipose tissue - glucose tolerance - insulin sensitivity
 

  • References

  • 1 Lijnen HR. Pleioptropic functions of plasminogen activator inhibitor-1. Thromb Haemost 2005; 03: 35-45.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors. Thromb Haemost 2004; 91: 425-37.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Shimomura I, Funahashi T, Takahashi M. et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 02: 800-3.
    CrossrefPubMedGoogle Scholar
  • 4 Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 02: 568-82.
    PubMedGoogle Scholar
  • 5 Alessi MC, Peiretti F, Morange P. et al. Production of plasminogen activator inhibitor1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-7.
    CrossrefPubMedGoogle Scholar
  • 6 Alessi MC, Bastelica D, Morange P. et al. Plasminogen activator inhibitor 1, transforming growth factor-beta 1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49: 1374-80.
    CrossrefPubMedGoogle Scholar
  • 7 Van Dielen FMH, Buurman WA, Hadfoune M. et al. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab 2004; 89: 4062-8.
    CrossrefPubMedGoogle Scholar
  • 8 Morange PE, Lijnen HR, Alessi MC. et al. Influence of PAI-1 on adipose tissue growth and on metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 2000; 20: 1150-4.
    CrossrefPubMedGoogle Scholar
  • 9 Lijnen HR, Maquoi E, Morange P. et al. Nutritionally induced obesity is attenuated in trangenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003; 23: 78-84.
    CrossrefPubMedGoogle Scholar
  • 10 Eren M, Su M, Atkinson J L. et al. Phenotypic derangements associated with overexpression of plasminogen activator inhibitor-1 (PAI-1) in transgenic mice. Arterioscler Thromb Vasc Biol 2001; 21: 695 (Abstract).
    PubMedGoogle Scholar
  • 11 Schafer K, Fujisawa K, Konstantinides S. et al. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. Faseb J 2001; 15: 1840-2.
    CrossrefPubMedGoogle Scholar
  • 12 Ma L-J, Mao S-L, Taylor KL. et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-46.
    CrossrefPubMedGoogle Scholar
  • 13 Lijnen HR. Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice. Thomb Haemost 2005; 93: 816-9.
    PubMedGoogle Scholar
  • 14 Elokdah H, Abou-Gharbia M, Hennan JK. et al. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: Design, synthesis, and preclinical characterization. J Med Chem 2004; 47: 3491-4.
    CrossrefPubMedGoogle Scholar
  • 15 Crandall DL, Elokdah H, Di L. et al. Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy. J Thromb Haemost 2004; 02: 1422-8.
    CrossrefPubMedGoogle Scholar
  • 16 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostatic model assessment: insulin resistance and β-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
    CrossrefPubMedGoogle Scholar
  • 17 Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-84.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Laitinen L. Griffonia Simplicifolia lectins bind specifically to endothelial cells and some epithelial cells in mouse tissues. Histochem J 1987; 19: 225-34.
    CrossrefPubMedGoogle Scholar
  • 19 Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-22.
    CrossrefPubMedGoogle Scholar
  • 20 Smith MD, Healy E, Thompson V. et al. Use of in situ detection of histone mRNA in the assessment of epidermal proliferation: comparison with the Ki-67 antigen and BrdU incorporation. Br J Dermatol 1995; 132: 359-66.
    CrossrefPubMedGoogle Scholar
  • 21 Lijnen HR, Van Hoef B, Lupu F. et al. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998; 18: 1035-45.
    CrossrefPubMedGoogle Scholar
  • 22 Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995; 74: 1305-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Maquoi E, Munaut C, Colige A. et al. Modulation of the expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 2002; 51: 1093-101.
    CrossrefPubMedGoogle Scholar
  • 24 Maquoi E, Demeulemeester D, Voros G. et al. Enhanced nutritionally induced adipose tissue development in mice with stromelysin-1 gene inactivation. Thromb Haemost 2003; 89: 696-704.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Rogers P, Webb GP. Estimation of body fat in normal and obese mice. Br J Nutr 1980; 43: 83-6.
    CrossrefPubMedGoogle Scholar
  • 26 Isomaa B, Almgren P, Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
    CrossrefPubMedGoogle Scholar
  • 27 Lakka HM, Laaksonen DE, Lakka TA. et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc 2002; 288: 2709-16.
    CrossrefPubMedGoogle Scholar
  • 28 Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obesity Res 2004; 12: 1197-211.
    CrossrefPubMedGoogle Scholar
  • 29 Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86: 324-33.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004; 28: 1357-64.
    CrossrefPubMedGoogle Scholar
  • 31 Mavri A, Alessi MC, Bastelica D. et al. Subcutaneous, abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia 2001; 44: 2025-31.
    CrossrefPubMedGoogle Scholar
  • 32 Reaven CM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993; 44: 121-31.
    CrossrefPubMedGoogle Scholar
  • 33 Juhan-Vague I, Alessi M-C, Mavri A. et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 01: 1575-9.
    CrossrefPubMedGoogle Scholar
  • 34 Eren M, Cleaves L, Walker E. et al. Inhibition of PAI-1 activity reduces angiotensin II induced aortic atherosclerosis and aneurysm in ApoE deficient mice. American Heart Association Meetings; 2003. Orlando, FL: (Abstract).
    Google Scholar
  • 35 Liu J, Antrilli TM, Elokdah H. et al. Inhibition of plasminogen activator inhibitor-1 protects against atherosclerosis progression in apolipoprotein E-deficient mice. Blood. 2003. 102 (11) Presented at the ASH meeting; San Diego: (Abstract).
    Google Scholar
  • 36 Weisberg AD, Albornoz F, Griffin JP. et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/ salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 2005; 25: 365-71.
    PubMedGoogle Scholar
  • 37 Smith LH, Dixon JD, Stringham JR, Eren M. et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006; 107: 132-34.
    CrossrefPubMedGoogle Scholar
  • 38 Lijnen HR, Alessi M-C, Van Hoef B. et al. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost 2005; 03: 1174-9.
    CrossrefPubMedGoogle Scholar
  • 39 Crandall DL, Quinet EM, El Ayachi S. et al. Modulation of adipose tissue development by pharmacologic inhibition of PAI-1. Arterioscler Thromb Vasc Biol 2006; 26: 2209-15.
    CrossrefPubMedGoogle Scholar
  • 40 Claret M, Corominola H, Canals I. et al. S23521 decreases food intake and body weight gain in diet-induced obese rats. Obes Res 2004; 12: 1596-603.
    CrossrefPubMedGoogle Scholar
  • 41 Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-70.
    CrossrefPubMedGoogle Scholar
  • 42 Devy L, Blacher S, Grignet-Debrus CK. et al. The pro-or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. Faseb J 2002; 16: 147-54.
    CrossrefPubMedGoogle Scholar
  • 43 Rupnick MA, Panigrahy D, Zhang CY. et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA 2002; 99: 10730-5.
    CrossrefPubMedGoogle Scholar
  • 44 Crandall DL, Hausman GJ, Kral JG. A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation 1997; 04: 211-232.
    CrossrefPubMedGoogle Scholar
  • 45 Voros G, Maquoi E, Demeulemeester D. et al. Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology 2005; 146: 4545-54.
    CrossrefPubMedGoogle Scholar